Promotion of tumor progression and cancer stemness by MUC15 in thyroid cancer via the GPCR/ERK and integrin-FAK signaling pathways

a Relative expression level of MUC15 between tumor (25 cases) and their neighboring normal thyroid tissue (27 cases) in thyroid cancer patients. b MUC15 Immunohistochemical (IHC) positivity in the patients was scored from 0 to 3 according to the percentage positivity (grade 0, 0%; grade 1, 1–33%; grade 2, 34–66%; grade 3, 67–100%). c Relative expression level of MUC15 normalized by GAPDH expression level among Nthy-ori-3-1, TPC-1, and FTC-238 cells. Western blots showing the expression level of the MUC15 protein. d Thyroid tumors have enhanced expression of MUC15 in patients according to TCGA database. e Immunostaining of MUC15 in Nthy-ori-3-1, TPC1 and FTC-238 cells, respectivel